Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against COVID-19 could reduce the success of cancer treatment ...
Nov 8, 2022
0
5
Nasopharyngeal carcinoma (NPC) is the most common malignant tumor of the head and neck in Southeast Asia and Southern China and originates from the epithelial tissue of the nasopharynx. Most NPCs are non-keratinizing cancers, ...
May 27, 2022
0
1
Chinese Americans and Laotian Americans were over 10 and 14 times more likely to be diagnosed with nasopharyngeal cancer, respectively, than non-Hispanic white Americans, with incidence rates surpassing other Asian American ...
Oct 6, 2021
0
16
A*STAR's Institute of Bioengineering and Nanotechnology (IBN) has teamed up with Singapore Institute of Advanced Medicine Holdings Pte Ltd (SIAMH) to establish the first of its kind in-vitro patient-derived 3D organoid models ...
Mar 31, 2021
0
9
(HealthDay)—Treatment at a high-volume facility (HVF) is a significant predictor of improved overall survival in nasopharyngeal cancer (NPC), according to a research letter published online Nov. 2 in JAMA Otolaryngology—Head ...
Nov 6, 2017
0
0
Scientists have the first major evidence that blood tests called liquid biopsies hold promise for screening people for cancer. Hong Kong doctors tried it for a type of head and neck cancer, and boosted early detection and ...
Aug 9, 2017
0
73
Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented ...
Dec 17, 2015
0
22
A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, National University Cancer Institute Singapore (NCIS) and National University Hospital Singapore ...
Jun 23, 2014
0
0
Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal ...
Nov 19, 2013
0
0
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.
Dec 16, 2011
0
0
